Livforsakringsbolaget Skandia’s Catalyst Pharmaceutical CPRX Stock Holding History

Livforsakringsbolaget Skandia’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-110,900	Closed	-$2.2M	–	576
2024 Q3	$2.2M	Buy	110,900 +36,000	+48%	+$667K	0.12%	131
2024 Q2	$1.16M	Hold	74,900	–	–	0.09%	157
2024 Q1	$1.19M	Hold	74,900	–	–	0.1%	158
2023 Q4	$1.26M	Hold	74,900	–	–	0.12%	157
2023 Q3	$873K	Sell	74,900 -3,500	-4%	-$46.8K	0.1%	176
2023 Q2	$1.05M	Sell	78,400 -3,900	-5%	-$56.1K	0.11%	160
2023 Q1	$1.36M	Buy	82,300 +26,600	+48%	+$439K	0.14%	146
2022 Q4	$1.04M	Hold	55,700	–	–	0.12%	161
2022 Q3	$713K	Hold	55,700	–	–	0.09%	168
2022 Q2	$390K	Hold	55,700	–	–	0.03%	264
2022 Q1	$462K	Hold	55,700	–	–	0.03%	281
2021 Q4	$377K	Buy	+55,700	New	+$366K	0.02%	323

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Livforsakringsbolaget Skandia's CPRX Position: Q4 2024 in Review

Livforsakringsbolaget Skandia sold out of Catalyst Pharmaceutical (CPRX) in Q4 2024, closing a stake of 110,900 shares — an estimated $2.2M sold.

Livforsakringsbolaget Skandia first reported a position in CPRX in Q4 2021 and held it in 12 quarters. The position peaked at $2.2M in Q3 2024. 336 funds tracked by Wall St. Rank hold CPRX as of Q4 2024.

Livforsakringsbolaget Skandia reported no remaining Catalyst Pharmaceutical position as of Q4 2024 after selling out during the quarter.
Livforsakringsbolaget Skandia sold 110,900 Catalyst Pharmaceutical shares in Q4 2024, an estimated $2.2M.
Livforsakringsbolaget Skandia first reported a position in Catalyst Pharmaceutical in Q4 2021 and held it in 12 quarters.
Livforsakringsbolaget Skandia's Catalyst Pharmaceutical position peaked at $2.2M in Q3 2024.
336 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2024.

Based on Livforsakringsbolaget Skandia's 13F filing for Q4 2024, filed 28 Jan 2025.